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Abstract
Background In patients with primary hyperoxaluria (PH), endogenous oxalate overproduction increases urinary oxalate excre-
tion, leading to compromised kidney function and often kidney failure. Highly elevated plasma oxalate (Pox) is associated with
systemic oxalate deposition in patients with PH and severe chronic kidney disease (CKD). The relationship between Pox and
estimated glomerular filtration rate (eGFR) in patients with preserved kidney function, however, is not well established. Our
analysis aimed to investigate a potential correlation between these parameters in PH patients from three randomized, placebo-
controlled trials (studies OC3-DB-01, OC3-DB-02, and OC5-DB-01).
Methods Baseline data from patients with a PH diagnosis (type 1, 2, or 3) and eGFR > 40 mL/min/1.73 m2 were analyzed for a
correlation between eGFR and Pox using Spearman’s rank and Pearson’s correlation coefficients. Data were analyzed by
individual study and additionally were pooled for Studies OC3-DB-02 and OC5-DB-01 in which the same Pox assay was used.
Results A total of 106 patients were analyzed. A statistically significant inverse Spearman’s correlation between eGFR and Pox
was observed across all analyses; correlation coefficients were − 0.44 in study OC3-DB-01, − 0.55 in study OC3-DB-02, − 0.51
in study OC5-DB-01, and − 0.49 in the pooled studies (p < 0.0064).
Conclusions Baseline evaluations showed a moderate and statistically significant inverse correlation between eGFR and Pox in
patients with PH already at early stages of CKD (stages 1–3b), demonstrating that a correlation is present before substantial loss
in kidney function occurs.
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Introduction
Primary hyperoxalurias (PHs) are a group of rare genetic dis-
orders caused by a range of defects in hepatic glyoxylate met-
abolic processes. Although the three identified forms of PH
(PH1, PH2 and PH3) are associated with mutations in differ-
ent genes (AGXT, GRHPR, and HOGA1, respectively), all are
characterized by endogenous overproduction of oxalate, a
byproduct of normal human metabolism that has low solubil-
ity [1–4]. Humans lack the enzymes required to metabolize
oxalate, therefore it is excreted primarily via the kidneys in
urine [5]. Patients with PH excrete high concentrations of
oxalate in the urine, leading to formation of calcium oxalate
(CaOx), which precipitates as crystals when urinary supersat-
uration occurs. Deposits of CaOx in the tubular lumen and
renal parenchyma can result in nephrocalcinosis and urolith-
iasis. Internalization of CaOx crystals leads to inflammation,
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decreased kidney function, and often kidney failure [2, 6–8].
In chronic kidney disease (CKD) stages 3b–4, plasma oxalate
(Pox) levels increase dramatically, ultimately depositing
CaOx systemically in organ systems throughout the body in
a potentially life-threatening process known as systemic
oxalosis [9, 10]. Once kidney failure occurs, intensive dialysis
regimens and eventually kidney transplantation, often in com-
bination with a liver transplantation, are required. The most
severe form of PH, type 1, accounts for approximately 80% of
cases [1, 11, 12].
Identification of robust endpoints for clinical trials is cru-
cial to permit earlier diagnosis and treatment of patients with
PH before the more severe complications of the disease arise.
Surrogate endpoints in clinical trials do not directly measure
the clinical benefit of the treatment in question; rather, they
can be useful as predictors of treatment efficacy, often by
using biomarkers such as laboratory measurements or physi-
cal signs [10], which could be tied to a clinical benefit.
Given the rarity of the disease [1], recruitment of patients
with PH to clinical trials is difficult and current treatment
options are limited. In patients with PH and advanced CKD
(stages 3b–5; estimated glomerular filtration rate (eGFR) <
45 mL/min/1.73 m2), highly elevated Pox is directly related
to the pathophysiology of oxalosis, and substantial change in
Pox may be used as a surrogate endpoint in a clinical setting
[10]. There are, however, discrepancies in the literature re-
garding the relationship of Pox and eGFR in patients with
earlier stages of CKD. Data from a recent study indicated that
there is a relationship between Pox and eGFR even for pa-
tients with less advanced stages of CKD (stages 1–3; mean
eGFR at baseline 111 mL/min/1.73 m2) [13]. In a registry of
mostly US patients with PH, a clear inverse correlation be-
tween Pox and eGFR across a broad range of kidney function
was observed [14]. Conversely, in a recent analysis of PH1
patients with stable kidney function from a European registry,
no significant correlation between Pox and eGFR was detect-
ed [15].
In order to gain a better understanding of the potential
association between Pox and eGFR in patients with PH and
eGFR > 40 mL/min/1.73 m2, we investigated the correlation
of these parameters using separate, and pooled, data from
three randomized, placebo-controlled trials that have previ-
ously been published [16–18].
Methods
Studies
The objective of all three interventional studies was to evalu-
ate the efficacy and safety of Oxalobacter formigenes, an an-
aerobic oxalate-degrading gut bacterium (Oxabact, OC3, or
OC5, OxThera Intellectual Property AB, Sweden) [19–21].
O. formigenes is suggested to reduce the endogenous oxalate
burden by promoting the removal of oxalate from the plasma
into the intestine via passive and active flux processes [22,
23].
The current analysis was based on individual and pooled
baseline data from three studies previously published which
are briefly summarized as follows:
Study OC3-DB-01 (ClinicalTrials.gov Identifier:
NCT00638703) was a phase 2/3, double-blind, randomized,
placebo-controlled, multicenter, international study conducted
in 42 patients with PH1 and PH2 between 2007 and 2008.
Patients received OC3 formulation (enteric-coated capsule)
or placebo twice daily for 24 weeks [16].
Study OC3-DB-02 (ClinicalTrials.gov Identifier:
NCT01037231) was a phase 2/3, double-blind, randomized,
placebo-controlled, multicenter, international study conducted
in 36 patients with PH1 and PH2 between 2010 and 2011.
Patients received OC3 formulation 500 mg (reconstituted
buffer solution) or placebo twice daily for 24 weeks [17].
Study OC5-DB-01 (ClinicalTrials.gov Identifier:
NCT02012985) was a phase 1/2, double-blind, randomized,
placebo-controlled, multicenter, international study conducted
in 28 patients with PH1, PH2 and PH3 between 2013 and
2015. Patients received OC5 formulation (enteric-coated
capsule) or placebo twice daily for 8 weeks [18].
All studies were performed in accordance with good clin-
ical practice (GCP) and the principles enshrined in the
Declaration of Helsinki, and were approved by the relevant
ethics committees. Patients were enrolled after providing writ-
ten, informed consent and/or parental consent, depending on
the age of the patient. The studies were designed, funded, and
managed by OxThera Intellectual Property AB (Stockholm,
Sweden).
Inclusion/exclusion criteria
Study OC3-DB-01 included patients aged ≥ 5 years with uri-
nary oxalate excretion > 1.0 mmol/1.73 m2/24 h and eGFR ≥
50 mL/min/1.73 m2. Study OC3-DB-02 and study OC5-DB-
01 included patients aged ≥ 2 years (≥ 5 years in the UK) with
urinary oxalate excretion > 1.0 mmol/1.73 m2/24 h and eGFR
≥ 40 mL/min/1.73 m2.
Estimated glomerular filtration rate
The eGFR equations used for the pediatric and adult popula-
tions, respectively, were Schwartz bedside 2009, eGFR =
0.413 × (height [cm]/(SCr) (where SCr is serum creatinine)
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Blood samples were obtained at baseline and processed for
determination of Pox. Plasma oxalate was analyzed using the
“free” Pox method in study OC3-DB-01 and using the “total”
Pox method in Studies OC3-DB-02 and OC5-DB-01. Free
Pox was measured by the oxalate oxidase assay [26, 27] in
which ultrafiltration of plasma removes proteins and circulat-
ing crystals, leaving only soluble oxalate for analysis. Normal
values for free Pox with this assay are in the range of 1–
3 μmol/L. Samples for free Pox determination were analyzed
at the Mayo Central Laboratory for Clinical Trials, Rochester,
USA.
Total Pox was measured using an isotope dilution mass
spectrometric assay (gas chromatography with mass selective
detection) [28]. The samples were first acidified to hydrolyze
proteins, release bound CaOx and to dissolve CaOx crystals,
and Pox was then extracted with ethylacetate prior to analysis.
Normal values for total Pox with this assay are in the range of
≤ 7 μmol/L. Samples for total Pox determination were ana-
lyzed at the Academic Medical Center, University of
Amsterdam, Netherlands.
Statistical methods
Analyses of studies OC3-DB-01, OC3-DB-02, and OC5-DB-
01 at baseline are presented individually. Pooled baseline data
were also evaluated for Studies OC3-DB-02 and OC5-DB-01.
Data from study OC3-DB-01 were not included in the pooled
analysis because the study used a different Pox assay, which
could have affected the correlation. Six patients were identi-
fied as having participated in more than one of the three trials;
their data was therefore only included once, in study OC3-
DB-02, when pooling data.
Descriptive statistics are provided as mean, median, stan-
dard deviation (SD), and range for continuous variables; fre-
quency and percentage are provided for categorical variables.
All values used were collected at baseline before study drug
administration. Patients were classified into CKD stages, ac-
cording to the National Kidney Foundation guidelines, based
on their baseline eGFR; study inclusion criteria permitted re-
cruitment of patients with CKD stages 1–3.
The association of eGFR with Pox was examined along
with characteristics of normal distribution and linear relation-
ship [29]. Based on indications of Pox and eGFR data being
nonnormally distributed, the nonparametric Spearman’s rank
correlation coefficient was primarily used providing an indi-
cation of the monotone association between eGFR and Pox.
The Pearson’s product-moment correlation coefficient, mea-
suring the strength of the linear relationship between eGFR
and Pox, and the coefficient of determination R2 (amount of
variance in eGFR explained by Pox) were calculated as sup-
plementary analyses. Scatterplots including the linear
regression line, corresponding regression equation and, for
the pooled data, a nonparametric smooth curve (local polyno-
mial regression) were generated, capturing the general data
trend based on local estimated scatterplot smoothing
(LOESS) procedure fitting [30]. The data included in our
analyses satisfied the independence assumption when evalu-
ating the regression and the Pearson’s product-moment linear
correlation coefficient. Results were not adjusted for multiple
testing. All statistical analyses were conducted using SAS
software (version 9.4; SAS Institute, Cary, NC, USA).
Results
Study population
A total of 106 patients were included: 42 patients from study
OC3-DB-01, 36 patients from study OC3-DB-02, and 28 pa-
tients from study OC5-DB-01 (Table 1). Primary
hyperoxaluria type 1 accounted for > 83% of diagnoses in
all three studies; only one patient had a diagnosis of PH3.
Median time since diagnosis was 5.7–9.0 years across studies.
Most patients in each study had CKD stages 1 or 2: 36 patients
(85.7%) in study OC3-DB-01, 29 patients (80.5%) in study
OC3-DB-02, and 27 patients (85.7%) in study OC5-DB-01.
No major differences in sex and age were found between
studies, and the majority of all study patients were recorded
as Caucasian or not African American.
Estimated glomerular filtration rate, plasma oxalate,
and urinary oxalate
There were no notable differences in median (range) eGFR
reported across studies at baseline (80.3 mL/min/1.73 m2
(42.4–160.0) in study OC3-DB-01, 80.8 mL/min/1.73 m2
(36.1–141.4) in study OC3-DB-02 and 81.3 mL/min/
1.73 m2 (34.3–159.9) in study OC5-DB-02). Median (range)
Pox was lower in study OC3-DB-01 at 6.5 μmol/L (1.6–25.2)
than in studies OC3-DB-02 and OC5-DB-01 (9.9 μmol/L
(4.5–35.0) and 12.5 μmol/L (4.6–43.1), respectively) at base-
line. The overall range for individual Pox values was 1.6–
43.1 μmol/L for the populations across all three studies.
There were no differences in baseline urinary oxalate between
the three studies; median (range) baseline urinary oxalate was
1.59 mmol/1.73 m2/24 h (1.02–3.13) in study OC3-DB-01,
1.79 mmol/1.73 m2/24 h (1.05–2.75) in study OC3-DB-02,
and 1.62 mmol/1.73 m2/24 h (0.90–3.08) in study OC5-DB-
01. Similarly, there were no differences in baseline urinary
oxalate per creatinine ratio values between the three studies;
median (range) baseline urinary oxalate per creatinine ratio
was 160.3 mmol/mol (65.3–451.8) in study OC3-DB-01,
178.8 mmol/mol (80.0–415.0) in study OC3-DB-02, and
146.7 mmol/mol (55.5–466.7) in study OC5-DB-01.
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Table 1 Demographic and baseline characteristics
OC3-DB-01 (N=42) OC3-DB-02 (N=36) OC5-DB-01 (N=28)
Age (years)
Mean 14.1 18.4 14.5
SD 6.7 14.5 5.6
Median 13.0 15.0 14.5
Min, Max 6, 39 3, 62 3, 27
Sex (n (%))
Male 19 (45.2) 19 (52.8) 15 (53.6)
Female 23 (54.8) 17 (47.2) 13 (46.4)
Race (n (%))
Caucasian 35 (83.3) 35 (97.2) N/A
Asian 5 (11.9) N/A N/A
Other 2 (4.8) 1 (2.8) N/A
African American/Black 0 N/A 1 (3.6)
Not African American N/A N/A 27 (96.4)
PH type (n (%))
Type 1 35 (83.3) 31 (86.1) 26 (92.9)
Type 2 7 (16.7) 5 (13.9) 1 (3.6)
Type 3 N/A N/A 1 (3.6)
Time since diagnosis (years)a
Mean 8.5 9.5 9.0
SD 5.9 10.0 5.3
Median 9.0 5.7 8.3
Min, Max −0.1b, 23.4 −0.1c, 41.6 1.3, 19.6
CKD stage (n(%))
Stage 1 15 (35.7) 16 (44.4) 12 (42.9)
Stage 2 21 (50.0) 13 (36.1) 12 (42.9)
Stage 3a 4 (9.5) 3 (8.3) 3 (10.7)
Stage 3b 2 (4.8) 4 (11.1) 1 (3.6)
eGFR (mL/min/1.73 m2)
Mean 83.4 83.8 86.6
SD 24.8 27.5 30.5
Median 80.3 80.8 81.3
Min, Max 42.4, 160.0 36.1, 141.4 34.3, 159.9
Pox (μmol/L)d
Mean 7.5e 12.1 14.7f
SD 5.1e 6.6 9.9f
Median 6.5e 9.9 12.5f
Min, Max 1.6, 25.2e 4.5, 35.0 4.6, 43.1f
Urinary oxalate (mmol/1.73 m2/24 h)g
Mean 1.77 1.80 1.74
SD 0.59 0.50 0.59
Median 1.59 1.79 1.62
Min, Max 1.02, 3.13 1.05, 2.75 0.90, 3.08
Urinary oxalate per creatinine ratio (mmol/mol)
Mean 184.4 179.6 174.0
SD 87.2 70.0 94.5
Median 160.3 178.8 146.7
Min, Max 65.3, 451.8 80.0, 415.0 55.5, 466.7
eGFR Estimated glomerular filtration rate; Max maximum; Min minimum; Pox plasma oxalate; SD standard deviation
a Date of written informed consent minus date of diagnosis
b One subject provided written informed consent but was kept in screening until a definitive primary hyperoxaluria diagnosis was made
cOne subject had a primary hyperoxaluria diagnosis two days after randomization; the patient was previously diagnosed before randomization, however,
the official diagnosis was lost between physicians
d Free plasma oxalate was calculated in study OC3-DB-01, while total plasma oxalate was calculated in studies OC3-DB-02 and OC5-DB-01
eN = 40
fN = 27
gUrinary oxalate was calculated without centrifuging in study OC5-DB-01
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Correlation between plasma oxalate and estimated
glomerular filtration rate
Scatter plots are presented displaying the relationship between
Pox and eGFR in study OC3-DB-01 (Fig. 1a), study OC3-
DB-02 (Fig. 1b), and study OC5-DB-01 (Fig. 1c). A moderate
and statistically significant inverse correlation between eGFR
and Pox was observed (p < 0.05) in each of the three studies
(Table 2), with Spearman’s correlation coefficients of − 0.44
in study OC3-DB-01, − 0.55 in study OC3-DB-02, and − 0.51
in study OC5-DB-01. Pooled data analyses from studies OC3-
DB-02 and OC5-DB-01 (Fig. 2) also resulted in a statistically
significant inverse correlation (p = 0.0001) between Pox and
eGFR when analyzing linear regression, with a Spearman’s
correlation coefficient of − 0.49. A statistically significant
nonlinear relationship was also observed when local polyno-
mial regression was used (Fig. 2; smooth line); the curve was
steeper at eGFR values less than approximately 100 mL/min/
1.73 m2 than those above.
Discussion
Our analysis of baseline (predose) Pox and eGFR data from
three randomized, placebo-controlled trials demonstrates a
statistically significant inverse moderate correlation between
eGFR and Pox in PH patients with CKD stages 1–3b. The
correlation between Pox and eGFR has generally been
thought to occur only in patients with advanced stages of
CKD (stages 3b–5) [14, 31]. Previous reports [1] suggested
that as a result of the better ability of kidneys to excrete excess
oxalate at higher eGFR levels, Pox and eGFR may not corre-
late well in early stages of CKD. In contrast, the correlation of
eGFR and Pox in the population reported in this analysis in-
dicates that elevations in Pox are observed before substantial
loss in kidney function has occurred. Thus, Pox may be a
factor in the development of kidney damage, and could pos-
sibly be considered as a leading indicator in itself. Data from
the pooled analysis suggests that the relationship between Pox
and eGFR is nonlinear across the range of eGFR values
assessed; the observed curve steepens when eGFR approaches
and falls below 100 mL/min/1.73 m2.
In the general population, Pox concentrations are often too
low to quantify, however our data suggest that in patients with
PH, Pox is quantifiable even when eGFR is preserved,
supporting its potential use as a biomarker [13, 14, 27]. The
observed correlation between Pox and eGFR at higher eGFR
ranges may support the utilization of Pox as a clinical trial
endpoint facilitating determination of efficacy in future PH in-
tervention studies in patients with CKD stages 1–3b. This con-
clusion is echoed by a recent consensus paper which supported
the use of elevated Pox levels in patients with compromised
kidney function (CKD stages 3b–5) as a likely surrogate end-
point for treatment efficacy, as well as proposing Pox as a
causal factor for nephrocalcinosis and kidney stones in patients
with preserved kidney function (CKD stages 1–3a) [10].
This is the first analysis to demonstrate a consistent correla-
tion between Pox and eGFR using data from several random-
ized, placebo-controlled studies; an appropriate study design is
paramount to acquiring high quality data, especially when the
data are necessary to drive treatment advancement in rare dis-
eases.While registry studies have provided significant informa-
tion in PH, and remain a valuable tool in analyzing character-
istics in patient populations, methodologies used are of impor-
tance in interpretation of results. For example, Pox concentra-
tions in registry studies can be influenced by differences in
methods used for sample handling, sample preparation, and
analysis of Pox samples. High intra- and interlaboratory vari-
ability in reported values can therefore occur due to this lack of
assay standardization, ultimately affecting diagnostic value and
evaluation of treatment efficacy [32]. A study comparing Pox
analysis methods used in patients with PH noted poor agree-
ment in Pox reporting between six laboratories [33]. In the
current analysis, we pooled data only from studies OC3-DB-
02 andOC5-DB-01 because both used the same instructions for
sample handling, the same Pox assay, and analyses were con-
ducted at the same laboratory. One further advantage of using
clinical trial data in our analyses is that the study protocols
defined clearly the eligibility criteria, permitted concomitant
medications and specific sampling time points, all of which
can be a source of variability in registry data.
In addition to study design and the assays used for deter-
mination of Pox concentrations, there are additional con-
founding factors that can influence the relationship between
Pox and eGFR, such as eGFR equations and intra- and indi-
vidual patient differences. Other limitations could include the
statistical methodology applied. Using primarily the nonpara-
metric Spearman’s rank correlation coefficient in our study
allowed us to assess the baseline data appropriately in the
three studies we describe; this complied with assumption of
data points independence, and normal distribution/linearity
were not violated.
Though there is substantial intersubject variability in the
progression and severity of disease, the effects of PH can be
devastating. Improvements in diagnostic procedures and
Table 2 Correlation between Pox and eGFR




Pooled: OC3-DB-02 and OC5-DB-01 −0.49 0.0001
a Spearman’s rank correlation coefficients are presented
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Fig. 1 Plasma oxalate (Pox) vs.
estimated glomerular filtration
rate (eGFR). Individual values of
Pox and eGFR in patients with
both values recorded at baseline
in a study OC3-DB-01 (n = 40), b
study OC3-DB-02 (n = 36), and c
study OC5-DB-01 (n = 27).
Baseline Pox was measured using
the free Pox method (study OC3-
DB-01) or total Pox method
(studies OC3-DB-02 and OC5-
DB-01). Pox = plasma oxalate.
eGFR= estimated glomerular fil-
tration rate
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disease management have increased median survival of pa-
tients with PH1—cohort studies suggest a median kidney sur-
vival of between 24 and 33 years [11, 34, 35]—yet there is
only a single, recently approved drug therapy for PH1 and no
approved drug therapies for PH2 and PH3. Our analysis has
certain limitations, chiefly that the low numbers of patients
with a diagnosis of PH2 or PH3 did not permit sufficient
statistical power to analyze the results by PH type. The ma-
jority of patients were Caucasian or not African American,
highlighting the need for further research into patients of other
racial and ethnic groups. Kidney function was estimated from
the Schwartz and MDRD equations for practical reasons in-
stead of formal measurement of GFR with, for instance,
iohexol. Finally, the cross-sectional design of our study does
not permit conclusions regarding a causal relationship between
Pox concentration and change in eGFR. Despite these limita-
tions, we demonstrate a statistically significant inverse correla-
tion of moderate strength between Pox and eGFR in PH1 pop-
ulations with CKD stages 1–3b. Other studies note the plausi-
bility of Pox being on the causal pathway for kidney damage,
that higher Pox concentrations can be a risk factor for kidney
failure [10], and suggest that Pox concentration could potential-
ly serve as a prognostic indicator of kidney function decline
[13]. While our data cannot fully support these conclusions,
the observed correlation at a single time point leads us to spec-
ulate that Pox concentration may at least serve as a marker for
kidney function. This represents an area for further research.
In conclusion, our data from the baseline analysis of three
randomized, placebo-controlled trials showed a statistically
significant inverse correlation between eGFR and Pox in pa-
tients with PH across a broad range of kidney function (eGFR
> 40 mL/min/1.73 m2 (CKD stage 1–3b)), and demonstrate
that Pox can be elevated at kidney function traditionally
regarded as normal. Prospective clinical studies are ongoing
to evaluate change in Pox and its relationship to clinical out-
come. Extensive research over the years has greatly advanced
the development of desperately needed treatments for PH, and
our study contributes to the growing body of evidence that
could aid development of new strategies to assess clinical
benefit in patients with PH.
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